EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 365 filers reported holding EXELIXIS INC in Q1 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $946,104 | +170369.2% | 49,900 | +69.2% | 0.00% | +100.0% |
| Q1 2023 | $555 | -12.2% | 29,500 | -25.1% | 0.00% | 0.0% |
| Q4 2022 | $632 | -99.9% | 39,400 | -28.4% | 0.00% | 0.0% |
| Q3 2022 | $871,000 | +8.2% | 55,000 | +42.2% | 0.00% | 0.0% |
| Q2 2022 | $805,000 | -10.8% | 38,686 | -3.8% | 0.00% | 0.0% |
| Q1 2022 | $902,000 | -30.5% | 40,200 | -42.3% | 0.00% | -50.0% |
| Q4 2021 | $1,298,000 | +0.2% | 69,658 | +10.8% | 0.00% | 0.0% |
| Q3 2021 | $1,296,000 | -7.6% | 62,841 | -19.6% | 0.00% | -33.3% |
| Q2 2021 | $1,402,000 | +53.2% | 78,114 | +87.4% | 0.00% | +200.0% |
| Q1 2021 | $915,000 | -36.9% | 41,684 | -41.9% | 0.00% | -50.0% |
| Q4 2020 | $1,450,000 | -30.3% | 71,745 | -15.4% | 0.00% | -60.0% |
| Q3 2020 | $2,079,000 | -15.0% | 84,848 | -21.1% | 0.01% | -28.6% |
| Q2 2020 | $2,445,000 | +27.1% | 107,600 | -0.6% | 0.01% | +16.7% |
| Q1 2020 | $1,923,000 | -15.2% | 108,200 | -15.5% | 0.01% | +20.0% |
| Q4 2019 | $2,269,000 | -33.1% | 128,040 | -32.1% | 0.01% | -54.5% |
| Q3 2019 | $3,394,000 | -21.6% | 188,593 | -6.9% | 0.01% | -8.3% |
| Q2 2019 | $4,328,000 | +101.4% | 202,502 | +124.3% | 0.01% | +71.4% |
| Q1 2019 | $2,149,000 | -4.0% | 90,301 | -21.6% | 0.01% | 0.0% |
| Q4 2018 | $2,239,000 | -7.8% | 115,179 | -16.0% | 0.01% | +16.7% |
| Q3 2018 | $2,428,000 | -25.2% | 137,040 | -6.4% | 0.01% | -25.0% |
| Q2 2018 | $3,244,000 | 0.0% | 146,457 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $3,244,000 | -43.0% | 146,457 | -21.8% | 0.01% | -60.0% |
| Q4 2017 | $5,696,000 | +57.6% | 187,378 | +25.6% | 0.02% | +42.9% |
| Q3 2017 | $3,615,000 | -21.9% | 149,193 | -31.7% | 0.01% | -44.0% |
| Q1 2017 | $4,631,000 | -14.7% | 218,447 | -40.0% | 0.02% | -7.4% |
| Q4 2016 | $5,430,000 | +8.4% | 364,221 | -10.7% | 0.03% | +12.5% |
| Q3 2016 | $5,010,000 | +194.7% | 408,000 | +87.3% | 0.02% | +140.0% |
| Q2 2016 | $1,700,000 | – | 217,879 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |